NameRosemary AaaaaaaaaaaAge46Known allergiesNKA Known medical conditionsHT, high cholesterol, diabetes Current therapy (brief)Avapro, Lipitor, Daonil Prescription details (for extemporaneous products, proprietary name is not required)
Poison schedule4 (n/a yet) Covered by PBSYes (n/a yet) * required for female patients only List up to four MAJOR indications for this product – which are POSSIBLE FOR THIS PATIENT – and the relevant dosage range or regimen for each, indicating the reference source (including year and page numbers) for the information. Indication Dosage range/regimen Reference Reduction of renal disease progression in patients with HT, type II diabetes and microalbuminuria Why do you think this product has been prescribed for this patient? If the product has been introduced as part of ongoing therapy for an existing condition, explain why this product has been added to therapy. HT not control ed by irbesartan alone, addition of diuretic is rational therapy
Faculty of Pharmacy - University of Sydney PHAR4620/PHAR5507
Student Name: Bench Number: Does the prescription (medication, quantity and directions) appear to be a rational and appropriate choice for this condition in this patient? Yes
(check one box). Give your reasons (briefly).
Patient changed from 150mg Avapro to same dose irbesartan plus hydrochlorthiazide. Thiazide diurectics reduce CV morbidity and mortality in patients with HT and diabetes
What common side effects might you expect to see associated with the use of this product? Note: Side Effects from addition of Thiazide only, ACE is continuing therapy. Dizziness, weakness, muscle cramps, polyuria, orthostatic hypotension, electrolyte changes, especial y hyperkalaemia What rare but dangerous side effects should you be aware of in relation to this product? Paraesthesia, intrahepatic cholestatic jaundice, cholecystitis, pancreatitis, agranulocytosis, aplastic anaemia, haemolytic anaemia, thrombocytopenia, toxic epidermal necrolysis, purpura, necrotising vasculitis
For remaining answers to questions please refer to your assignment with marker’s comments.
Faculty of Pharmacy - University of Sydney PHAR4620/PHAR5507
Convergent Software & ISO 28560-2 Conformance Document The bit and byte ordering discussed in the ISO 28560-2 Guidelines for development of ISO 28560-2 conformant devices (direct link: http://biblstandard.dk/rfid/docs/conformance_28560-2.pdf) explains that there is a complex relationship between the various components between the application (for example the Library Management System)